SecBot SecBot

GTBP

GT Biopharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000109657 Biotech & Drug Discovery
$3.54 −0.18 (−4.97%)
Nov 16 4:00 PM ET · prev $3.72
Market cap
$7.9M
Nano cap
Median target
$75.00
+2022% · range $75.00–75.00
1 year
+414.6%
from $0.6870 · Nov 17
30 days
−47.2%
from $6.69
52-week range
$0.6080–20.42
−83% from high · low Dec 3
Avg volume 20D
79.6K
shares / day
Short interest
246.5K
≈12.0% of shares · −11.6%
Days to cover
3.2
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 4 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 2 trimmed or exited.

  • Short sellersSTEADY

    Short interest −11.6% to 246.5K shares. 3.2 days to cover, ≈12.0% of shares.

  • TrendDOWNTREND

    42% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
OSAIC HOLDINGS, INC.ADD38,500$18.9K
MORGAN STANLEYADD22,573$11.1K
ROYAL BANK OF CANADADOUBLED7,600$4.0K
BNP PARIBAS FINANCIAL MARKETSTRIM6$3.00
UBS Group AGNEAR_EXIT2$1.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED294,459$120.2K
UBS Group AGDOUBLED45,970$18.8K
LPL Financial LLCDOUBLED30,382$12.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Dec 2024
12-month targets · 1 analysts

Price is below the lowest target. Median implies +2022%.Targets as of Nov 12, 2026.

Recent actions
DateFirmActionRating
Dec 2, 2024Roth MKM
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$0.00
Next QNoneNoneNo data$0.00
Current FYNoneNoneNo data$0.00
Next FYNoneNoneNo data$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 16, 2026
Earnings
🔒 Fresh data, subscribers only
Nov 16, 2026
Earnings date
🔒 Fresh data, subscribers only
Nov 12, 2026
Earnings date
GTBP Q3 2026 Earnings Scheduled · 2026-11-12
Oct 26, 2026
Company news
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology…
Sep 22, 2026
Listing
Listing Status: GTBP, Normal (was Deficient)
GT Biopharma, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N

Short side

FINRA· Oct 30, 2026
246,479
shares short
-11.6%
vs prior settlement
3.2
days to cover
≈12.0%
of shares outstanding
Trading halts
Sep 15, 2026Volatility PauseResumed
Sep 4, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

SecBot reports

11 filings · 1 press release · 0 bullish · 7 bearish · 4 neutral
All GTBP filing & press-release reports (12)